DBV Technologies (DBVT) FCF Margin (2020 - 2026)
DBV Technologies (DBVT) posted FCF Margin of 7571.43% for Q2 2026, down 37.66% sequentially from 5500.0% in Q1 2026, and down 531143.0% YoY from N/an in Q2 2025.
Powered by 
Analysis
DBV Technologies (DBVT) FCF Margin (2020 - 2026) Analysis & Trends
DBV Technologies has reported FCF Margin for 7 years, with the latest figure at 7571.43% in Q2 2026.
- Quarterly FCF Margin fell 531143.0% year-over-year to 7571.43% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3399.34% (down 114654.0% YoY) and the FY2025 annual result came in at 2159.56%, up 38358.0% from the prior year.
- FCF Margin slipped to 7571.43% in Q2 2026 per DBVT's latest filing, from 5500.0% in the prior quarter.
- Over five years, FCF Margin peaked at 1832.59% in Q4 2022 and troughed at 7571.43% in Q2 2026.
- A 5-year average of 2077.03% and a median of 1652.91% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2026: FCF Margin jumped 250449 bps in 2022, then sank 531143 bps in 2026.
- Over 5 years, FCF Margin stood at 1832.59% in 2022, then tumbled by 109 bps to 158.17% in 2023, then tumbled by 1269 bps to 2165.54% in 2024, then slumped by 154 bps to 5511.01% in 2025, then slumped by 37 bps to 7571.43% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 7571.43%, 5500.0%, and 5511.01% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | DBV Technologies | 5.88 Bn | 5.70 Bn | - | -7,571.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,571.43% |
| Mar 31, 2026 | -5,500.00% |
| Dec 31, 2025 | -5,511.01% |
| Sep 30, 2025 | -1,174.01% |
| Jun 30, 2025 | -2,260.00% |
| Mar 31, 2025 | -2,462.50% |
| Dec 31, 2024 | -2,165.54% |
| Sep 30, 2024 | -2,131.81% |
| Jun 30, 2024 | -3,083.98% |
| Mar 31, 2024 | -2,560.55% |
| Dec 31, 2023 | -158.17% |
| Sep 30, 2023 | -827.28% |
| Jun 30, 2023 | -1,123.99% |
| Mar 31, 2023 | -954.97% |
| Dec 31, 2022 | 1,832.59% |
| Sep 30, 2022 | -984.62% |
| Jun 30, 2022 | -685.94% |
| Mar 31, 2022 | -63.39% |
| Dec 31, 2021 | -671.90% |
| Sep 30, 2021 | -1,733.64% |